Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Cash & Equivalents (2023 - 2026)

Beta Bionics' Cash & Equivalents history spans 4 years, with the latest figure at $30.2 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents fell 28.85% to $30.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $30.2 million, a 28.85% decrease, with the full-year FY2025 number at $31.6 million, up 3.76% from a year prior.
  • Cash & Equivalents hit $30.2 million in Q1 2026 for Beta Bionics, down from $31.6 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for BBNX hit a ceiling of $42.5 million in Q1 2025 and a floor of $13.0 million in Q2 2024.
  • Historically, Cash & Equivalents has averaged $28.7 million across 4 years, with a median of $30.3 million in 2024.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 169.21% in 2025 and later decreased 28.85% in 2026.
  • Tracing BBNX's Cash & Equivalents over 4 years: stood at $26.6 million in 2023, then rose by 14.55% to $30.4 million in 2024, then increased by 3.76% to $31.6 million in 2025, then decreased by 4.34% to $30.2 million in 2026.
  • Business Quant data shows Cash & Equivalents for BBNX at $30.2 million in Q1 2026, $31.6 million in Q4 2025, and $38.5 million in Q3 2025.